SecBot SecBot
Biotech Drug Report Generated Jul 9, 2026

AXS-07

AXSM·Axsome Therapeutics, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially launched (January 30, 2025)
Why 4/10
AXS-07 (SYMBRAVO) is already FDA-approved (January 30, 2025) and commercially launched, there is no pending PDUFA, pivotal readout, or hard binary catalyst for this specific drug in the next ~12 months. The impact score reflects that it is an approved product in early commercial ramp, making up a small portion ($4.1M Q1 revenue) of a multi-product company where bigger catalysts (AUVELITY Alzheimer's agitation launch, pipeline readouts) dominate the thesis.
Actionable Insight NEUTRAL

AXS-07 is already approved and generating early revenue, so its binary risk is behind it. For an AXSM investor, watch SYMBRAVO prescription trends and payer access as leading indicators of commercial traction, but the bigger near-term stock drivers are AUVELITY's Alzheimer's agitation launch and pipeline catalysts for AXS-12/solriamfetol.

Price Chart

Loading chart...

Executive Summary

AXS-07 (brand name SYMBRAVO) is an FDA-approved oral migraine medication from Axsome Therapeutics combining meloxicam (NSAID) and rizatriptan (triptan) using MoSEIC rapid-absorption technology. It was approved January 30, 2025 for acute migraine in adults after positive Phase 3 data. Early commercial launch generated $4.1M in Q1 2026 revenue. The drug is now a marketed product rather than a binary catalyst, its approval risk is resolved, and commercial execution is the watchpoint. AXS-07 is one of three commercial products at Axsome, where AUVELITY ($153M quarterly revenue) is the dominant value driver.

How It Works

AXS-07 is a two-drug combination pill for migraine. One component (meloxicam) is an NSAID that reduces inflammation and blocks CGRP (a protein involved in migraine pain). The other (rizatriptan) is a triptan that constricts dilated blood vessels in the brain and blocks pain signals. The MoSEIC technology makes both drugs absorb faster, giving quicker relief.

Trial Status

Phase 3 MOMENTUM and INTERCEPT trials met co-primary and key secondary endpoints. The EMERGE open-label Phase 3 trial in CGRP-inadequate responders is completed. Pooled Phase 3 analyses published April 2024 showed efficacy on pain freedom, most bothersome symptoms, and reduced rescue medication use. FDA approved January 30, 2025 following a CRL in May 2022 (CMC issues, since resolved).

The Two-Sided Case

▲ Bull Case4
SYMBRAVO fills a clear niche: patients who need faster-acting migraine relief than oral CGRP inhibitors (gepants) or who had inadequate response to triptans alone, the EMERGE trial specifically studied CGRP-inadequate responders.
The combination multi-mechanistic approach (NSAID + triptan) differentiates it from single-mechanism competitors; Phase 3 data showed pain freedom as early as 30 minutes post-dose.
Analyst consensus on AXSM is Strong Buy (25 buy/strong buy vs 2 hold) with a mean price target of $276.56, implying ~45% upside from recent levels. Top-tier firms (RBC, HC Wainwright, Needham, Mizuho) maintain Outperform/Buy ratings.
Early revenue of $4.1M in Q1 2026 is from initial launch, the product has patent protection to 2036 and rides on existing Axsome CNS commercial infrastructure.
▼ Bear Case4
SYMBRAVO is entering a crowded acute migraine market with entrenched generic triptans, established branded gepants (Pfizer/Biohaven's Nurtec with ~$1B+ annual sales, AbbVie's Ubrelvy), and Lilly's Reyvow, competing for payer coverage and mindshare will be expensive.
Early launch revenue of just $4.1M in Q1 2026 is modest relative to Axsome's $191M total revenue; SYMBRAVO is a small contributor and may never reach blockbuster status in this competitive field.
The drug has a complex regulatory history, a prior CRL in May 2022, and the approval came via a Class 2 resubmission, indicating CMC/manufacturing risks were only recently resolved.
Axsome is still unprofitable (GAAP EPS -$1.26 in Q1 2026 missed consensus by 46.5%), and heavy SG&A/R&D spending to support the SYMBRAVO launch and pipeline may pressure the stock.

Upcoming Catalysts

  • SYMBRAVO prescription and revenue trajectory in upcoming quarterly earnings reports
  • Potential payer/formulary coverage decisions and market access milestones
  • New SYMBRAVO data presentations at medical conferences (e.g., AHS 2026 data presented June 2026)
  • Possible label expansion or pediatric study initiation (no formal catalyst announced yet)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Axsome Therapeutics, Inc. COURT-RULING AXSM ·Originating report

Sources · 10

Hover a chip for the title
1 biospace.com2 drugs.com3 hcplive.com4 biospace.com5 neurologylive.com6 pharmacytimes.com7 clinicaltrials.gov8 accessdata.fda.gov9 axsome.com10 sec.gov